3-CARBAMOYLPHENYL-4-CARBOXAMIDE AND ISOPHTALAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY
European Patent Office Patent
Stats

Importance

EP Family Size
|
Non-US Coverage
|
Abstract
The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients, in which: R1 represents a group selected from: C1-C3-alkoxy-C2-C5-alkyl-, (A), (B), (C), (D), (E), (F), (G) or (H); wherein * indicates the point of attachment to the rest of the molecule; R2 represents a group selected from: (I), (J) or (K); wherein * indicates the point of attachment to the rest of the molecule.

First Claim
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Country Designations

Patent Owner(s)
Patent Owner | Address |
---|---|
BAYER PHARMA AG | DEBERLIN GERMANY |
International Classification(s)
Inventor(s)
Inventor Name | Address |
---|---|
THEDE KAI | JABLONSKISTR 26 10405 BERLIN |
LIENAU PHILIP | JAHNSTR 13 10967 BERLIN |
MÖNNING URSULA | 15569 WOLTERSDORF |
HÄGEBARTH ANDREA | 10247 BERLIN |
LIU NINGSHU | LIMONENSTR 28 12203 BERLIN |
GOLZ STEFAN | SPERLINGSTR 17 45472 MÜLHEIM AN DER RUHR |
PUHLER FLORIAN | 02142 CAMBRIDGE |
ZORN LUDWIG | OSIANDERWEG 45A 13509 BERLIN |
RICHTER ANJA | SCHÜTZENSTR 18 12105 BERLIN |
SIEGEL FRANZISKA | BERLIN |
BENDER ECKHARD | GUDRUNSTR 6 WOHNUNG 9 40764 LANGENFELD |
SCOTT WILLIAM J | GUILFORD CT |
BASTING DANIEL | DÜSSELDORFER STR 127 51063 KÖLN |
MÖWES MANFRED | 12163 BERLIN |
SCHNEIDER DIRK | 51519 ODENTHAL |
Cited Art Landscape
- No Cited Art to Display

Full Text

Legal Events

Matter Detail

Renewals Detail

Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:

Add to additional portfolios:

Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement

Recipient Email Address

Recipient Email Address

Comment
Recipient Email Address

Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
Important Notes on Latency of Status data
This Status indicator is an estimation based on the relevant document kind code. As such, it status will only indicate "Published" or "Granted". Expired, lapsed or abandoned statuses are not available in this release. Please refer to the legal status information for more information.
This status should not be taken as legal conclusion. No representations are made as to the accuracy of the status provided. Please consult a legal professional before relying on this status information.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
Only for Granted EP cases
EP validations represent the countries in which the EP patent may be in force. Data is based on reporting from the various EP contracting states. The reporting consistency can vary across the countries.